Blood Dialyzer Market is expected to grow at a CAGR of 6.8% during the forecasting period (2023-2030). North America dominates the market for blood dialyzers and is expected to show a similar trend over the forecast period. Competitive rivalry intensifies with Nikkiso Co. Ltd, B. Braun Medical Inc, Nipro Corporation, and others operating in the market.
Metrics |
Details |
Market CAGR |
6.8% |
Segments Covered |
By Product Type, By Material, By Membrane Type, By Dialysis Membrane Material, By Usability, By End User, and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
To Get a Free Sample Click here
During hemodialysis, the patient's blood is pumped through a dialyzer filter. The dialysis machine pumps blood through the filter and returns the blood to the patient body. During the process, the dialysis machine checks patient’s blood pressure and controls how quickly.
The global blood dialyzer market growth is driven by technological advancements, an increasingly aging population, a rising prevalence of diabetics and kidney disease, rising patient awareness, growing funding for research and development, rising patient healthcare expenditure and a shortage of kidney transplantation.
The increasing number of chronic diseases, such as kidney disease and technological advancements drive the market worldwide. As per the article published in Kidney International Supplementation in March 2022, chronic kidney disease is a developed disease that involves more than 10% of the general population worldwide, amounting to more than 800 million individuals. Chronic kidney disease is more prevalent in older individuals, women, racial minorities, and people experiencing diabetes mellitus and hypertension. Chronic kidney disease represents an especially large burden in low- and middle-income countries, which are small and equipped to deal with its effects. Chronic kidney disease has emerged as one of the leading causes of mortality worldwide. It is one of a few non-communicable diseases that have increased associated deaths over the past 2 decades. Hemodialysis is the one way to treat kidney failure and can help continue the active life of patients. Rising kidney disease patients lead to increasing demand for blood dialyzers.
In addition, the market players are adopting the market strategies such as collaboration and product launches to expand their business. For instance, on May 26, 2022, DaVita Inc. declared the plan to form a new, separate kidney care-focused medical device company to improve the patient treatment experience and overall outcomes. The Company will focus on developing a broad suite of novel kidney care products and solutions to make different dialysis treatments more accessible to patients, including future home-based products.
Also, in September 2021, Fresenius Medical Care reported a strategic distribution partnership with JMS Co. Ltd, a provider of medical devices and pharmaceuticals, in Japan. Under the agreement, JMS Co. Ltd. will distribute Fresenius Medical Care’s innovative home dialysis therapies in the Japanese market, providing patients with a wider range of dialysis choices to suit their lifestyles, enhance their well-being, and help address the home healthcare needs of Japan’s aging population.
However, the side effects of hemodialysis include low blood pressure, muscle cramps, itching, sleep problems, anemia, bone disease, high blood pressure, fluid overload, inflammation of the heart's membrane, and high potassium level. These adverse effects limit the market growth.
The COVID-19 pandemic has profound adverse effects on the population on dialysis. Patients requiring dialysis are at an increased risk of SARS-CoV-2 infection and mortality, and many have experienced psychological distress and delayed or suboptimal care.
According to Johns Hopkins University, in March 2022, more than 30% of patients hospitalized with COVID-19 developed kidney injuries, and more than 50% of patients in the intensive care unit (ICU) with kidney injuries may require dialysis earlier in the pandemic. Some hospitals were operating short on machines and sterile fluids required to perform dialysis.
As treatments for patients with COVID-19 have enhanced, dialysis rates have decreased. Shortages of machines and intermittent supply chain disruptions are other challenges. In addition, dialysis shifts were modified to isolate potential COVID-19 cases, and terminal disinfection was conducted after each dialysis shift. Now over one year into this pandemic and with vaccination providing the real hope for eventual containment, the picture arising from the early pandemic period is of dialysis staff working bravely to keep patients safe and cared for and of dialysis patients doing their utmost to reduce their infection risk.
The hospital segment accounts for the highest market share. Dialysis is done in a hospital, a clinic associated with a hospital, or a freestanding clinic. Hospitals are staffed with physicians, nurses, and patient-care technicians, all participating in care. In general, in-center or hospital hemodialysis takes between three and five hours (the average is three-and-a-half to four hours) and is done three times a week.
In addition, in some cases, unlike regular dialysis, which takes 3-4 hours, continuous dialysis runs 24 hours daily. It is increasingly used in intensive care units for patients with acute kidney failure because it is far gentler on the body. Increasing the patient in hospitals with kidney failure drives the market.
In addition, product approval by FDA drives the market. For instance, in December 2020, Medtronic launched its Carpediem Cardio-Renal Paediatric Dialysis Emergency Machine in the United States upon receiving Food and Drug Administration's (FDA) marketing authorization. The first machine was installed at Cincinnati Children's Hospital Medical Center.
North America dominates the market for blood dialyzers and is expected to show a similar trend over the forecast period. The market is driven by technological advancements, the rising prevalence of kidney disease, and product launches by market players in the North American region.
According to the Centers for Disease Control and Prevention 2021 report, chronic kidney disease is more familiar in people aged 65 years or older (38%) than in people aged 45–64 years (12%) or 18–44 years (6%). Chronic kidney disease is slightly more typical in women (14%) than men (12%). The rising number of kidney disease patients leads to increasing market demand.
In addition, the market players are adopting the market strategies such as collaboration and product launches. For instance, In January 2022, NextKidney acquired Dialysis to boost the development of its portable Neokidney hemodialysis device.
The blood dialyzer market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Baxter International, Inc., Nikkiso Co. Ltd., B. Braun Medical Inc., Nipro CCompetitive Landscape of orporation, CVS Health, Diaverum Deutschland GmbH, Fresenius Medical Care AG & Co. KGaA, DaVita Healthcare Partners, Inc., Asahi Kasei Corporation, and Browndove Healthcare (P) Ltd, among others. The major players are adopting several growth strategies, such as Type launches, acquisitions, and collaborations, contributing to the growth of the blood dialyzer market globally.
For instance,
Overview:
Baxter International Inc. is a multinational healthcare organization founded in 1931 and headquartered in Illinois, United States. The company mainly focuses on products to treat kidney disease, and other chronic and acute medical conditions
Homechoice Claria Automated Peritoneal Dialysis System: The Homechoice Claria automated peritoneal dialysis system offers the Sharesource remote patient management platform with user-friendly features that help end-stage renal disease patients manage their home peritoneal dialysis therapy while keeping them connected remotely with their healthcare providers.
The global blood dialyzer market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.
$4350
$4350
$4350
$4350
$4350
$4350